Beam Therapeutics Inc. (BEAM)

NasdaqGS: BEAM · 即時價格 · USD

23.99

-0.38 (-1.56%)

收盤價： Sep 11, 2026, 3:59 PM

24.12

+0.54%

盤後: 7:58 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

-1.56% (1D)

買價	17.57
市值	2.48B
營收 (ttm)	156M
淨利（ttm）	-86.5M
	2.23
	-0.69
	n/a
	-5.06
P/B (ttm)	2.25
P/S (ttm)	15.88
財報日期	Nov 3, 2026

賣價	30.83
成交量	1,192,476
20 日平均成交量	2,173,073
開盤價	24.64
前收盤價	24.37
當日區間	23.95 - 24.76
52 週範圍	20.23 - 38.26
分析師	強<br>購買
目標價	45 (87.58%)
股利	n/a
除息日	n/a

關於 BEAM

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Feb 6, 2020

員工 540

證券交易所 NasdaqGS

股票代號 BEAM

網站 https://beamtx.com

完整的公司簡介

財務表現

Beam Therapeutics 在 2025 年的營收為 139.74M，較前一年的 63.52M 增加 120.01%。淨利為 -79.99M，較前期減少 -78.77%。

財務報表

分析師預測

根據 13 位分析師的評等，BEAM 的平均評等為「Strong Buy」。12 個月目標價為 45，較最新價格有 87.58% 的上漲空間。

股票預測

財報驚奇

Beam Therapeutics 已於 Aug 4, 2026 公布季度財報：

營收為 $490K 低於預期 $0, 年增 -94.21% 下滑.
每股盈餘為 -1.18 低於預期 -0.05, 年增 -18.00% 下滑.

下次財報發布

Beam Therapeutics Inc. 的下次財報預計於 Nov 3, 2026, 開盤前。
分析師預估營收 ... 升級

價格為何變動

新聞動態

2 天前 · Insider Monkey

Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit?

Beam Therapeutics Inc. (NASDAQ:BEAM) reported updated Phase 1/2 results on September 8 for BEAM-302, an investigational gene-editing treatment for alpha-1 antitrypsin deficiency, or AATD. Although 38 ...

4 天前 · Zacks

3 Promising Genomics Stocks in the Spotlight in 2026

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

4 天前 · Benzinga

Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment

Beam Therapeutics Inc. (NASDAQ:BEAM) on Tuesday presented updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD). AATD is a hereditar...

2 週前 · Simply Wall St.

Beam Therapeutics (BEAM) Stock May Look Stretched As Sales Expectations Climb

Beam Therapeutics has delivered a sharp 86.5% share price gain over the past year, yet the stock screens as expensive on broader valuation checks, which leaves recent buyers paying up for its gene edi...

2 週前 · Zacks

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.

第 1 頁，共 2 頁

Beam Therapeutics Inc. (BEAM)